Dezerv

Fund Overview

Fund Size

Fund Size

₹31 Cr

Expense Ratio

Expense Ratio

0.34%

ISIN

ISIN

INF277KA1BG3

Minimum SIP

Minimum SIP

₹1,000

Exit Load

Exit Load

No Charges

Inception Date

Inception Date

26 Apr 2024

About this fund

This fund has been in existence for 1 months and 1 days, having been launched on 26-Apr-24.
As of 24-May-24, it has a Net Asset Value (NAV) of ₹10.07, Assets Under Management (AUM) of 31.50 Crores, and an expense ratio of 0.34%.
  • Tata Nifty MidSmall Healthcare Index Fund Direct Growth has given a CAGR return of 0.65% since inception.
  • The fund's asset allocation comprises around 99.71% in equities, 0.00% in debts, and 0.29% in cash & cash equivalents.
  • You can start investing in Tata Nifty MidSmall Healthcare Index Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

Since Inception

+0.65%

(Cat Avg.)

Portfolio Summaryas of 30th April 2024

Equity31.41 Cr99.71%
Others0.09 Cr0.29%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Max Healthcare Institute Ltd Ordinary SharesEquity4.43 Cr14.06%
Lupin LtdEquity2.84 Cr9.00%
Aurobindo Pharma LtdEquity2.32 Cr7.35%
Alkem Laboratories LtdEquity1.73 Cr5.50%
Fortis Healthcare LtdEquity1.63 Cr5.18%
Ipca Laboratories LtdEquity1.29 Cr4.08%
Laurus Labs LtdEquity1.26 Cr4.01%
Mankind Pharma LtdEquity1.22 Cr3.86%
Glenmark Pharmaceuticals LtdEquity1.13 Cr3.58%
Abbott India LtdEquity1 Cr3.18%
J.B. Chemicals & Pharmaceuticals LtdEquity0.97 Cr3.08%
Biocon LtdEquity0.95 Cr3.00%
Global Health LtdEquity0.94 Cr2.99%
Syngene International LtdEquity0.89 Cr2.82%
Gland Pharma LtdEquity0.84 Cr2.68%
Krishna Institute of Medical Sciences LtdEquity0.71 Cr2.25%
Ajanta Pharma LtdEquity0.69 Cr2.19%
Natco Pharma LtdEquity0.66 Cr2.10%
Piramal Pharma LtdEquity0.62 Cr1.98%
Dr. Lal PathLabs LtdEquity0.62 Cr1.97%
Narayana Hrudayalaya LtdEquity0.62 Cr1.97%
GlaxoSmithKline Pharmaceuticals LtdEquity0.61 Cr1.92%
Sanofi India LtdEquity0.53 Cr1.69%
Poly Medicure LtdEquity0.53 Cr1.68%
Rainbow Childrens Medicare LtdEquity0.49 Cr1.55%
Suven Pharmaceuticals LtdEquity0.48 Cr1.52%
Granules India LtdEquity0.41 Cr1.30%
Alembic Pharmaceuticals LtdEquity0.39 Cr1.25%
Metropolis Healthcare LtdEquity0.33 Cr1.05%
Aster DM Healthcare Ltd Ordinary SharesEquity0.29 Cr0.91%
Cash / Net Current AssetCash0.09 Cr0.29%

Allocation By Market Cap (Equity)

Large Cap Stocks

3.86%

Mid Cap Stocks

62.80%

Small Cap Stocks

33.06%

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare31.41 Cr99.72%

Risk & Performance Ratios

Standard Deviation

This fund

--

Cat. avg.

--

Lower the better

Sharpe Ratio

This fund

--

Cat. avg.

--

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

--

Higher the better

Fund Managers

KM

Kapil Menon

Since April 2024

Additional Scheme Detailsas of 30th April 2024

ISININF277KA1BG3Expense Ratio0.34%Exit LoadNo ChargesFund Size₹31 CrAge26 Apr 2024Lumpsum Minimum₹5,000Fund StatusOpen Ended Investment CompanyBenchmarkNifty MidSmall Healthcare Index (TRI)

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Withdrawal within 1 year

Flat 15% tax on realised gains (STCG - short term capital gains)

Withdrawal after 1 year

10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)

Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Index Funds Funds

Fund nameExpense RatioExit LoadFund size
1Y
ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth

Very High Risk

0.3%0.0%₹399.16 Cr58.3%
ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth

Very High Risk

0.9%0.0%₹399.16 Cr57.3%
ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth

Very High Risk

1.0%0.0%₹156.71 Cr73.5%
SBI Nifty Midcap 150 Index Fund Regular Growth

Very High Risk

1.0%0.0%₹400.29 Cr57.7%
DSP Nifty 50 Equal Weight Index Fund Regular Growth

Very High Risk

1.0%0.0%₹1345.87 Cr37.4%
SBI Nifty Smallcap 250 Index Fund Direct Growth

Very High Risk

0.4%0.0%₹711.53 Cr63.1%
SBI Nifty Midcap 150 Index Fund Direct Growth

Very High Risk

0.4%0.0%₹400.29 Cr58.6%
ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth

Very High Risk

0.3%0.0%₹156.71 Cr74.6%
DSP Nifty 50 Equal Weight Index Fund Direct Growth

Very High Risk

0.4%0.0%₹1345.87 Cr38.1%
SBI Nifty Smallcap 250 Index Fund Regular Growth

Very High Risk

1.0%0.0%₹711.53 Cr62.1%

Risk Level

Your principal amount will be at Very High Risk

Very High Risk
Wealth Monitor

Unlock Expert Insights!

Maximise Returns with our Wealth Monitor App. Try it now!

Still got questions?
We're here to help.

The NAV of Tata Nifty MidSmall Healthcare Index Fund Direct Growth, as of 24-May-2024, is ₹10.07.
The fund's allocation of assets is distributed as 99.71% in equities, 0.00% in bonds, and 0.29% in cash and cash equivalents.
The fund managers responsible for Tata Nifty MidSmall Healthcare Index Fund Direct Growth are:-
  1. Kapil Menon